Panacea Biotec disclosed zero shares were dematerialized during April 2026 in a mandatory SEBI regulatory filing.
Total dematerialized shares remained unchanged at 6,11,04,526 as of April 30, 2026, split between NSDL and CDSL.
The disclosure was certified by the company's RTA, Skyline Financial Services Pvt. Ltd., and submitted to BSE and CDSL.